-+ 0.00%
-+ 0.00%
-+ 0.00%

Biomea Fusion says icovamenib boosts C-peptide in 52-week Phase 2 type 1 diabetes trial

PUBT·04/27/2026 21:37:53
Listen to the news
Biomea Fusion says icovamenib boosts C-peptide in 52-week Phase 2 type 1 diabetes trial
  • Biomea Fusion reported positive 52-week Phase 2 COVALENT-112 results for oral icovamenib in adults with type 1 diabetes, with data already released ahead of a fuller presentation at ADA Scientific Sessions in June.
  • Treatment signaled improved insulin production in recently diagnosed patients, with effects that largely held through one year following a short dosing period.
  • Patients with longer-standing disease also showed preservation of insulin production over the 52-week observation period.
  • Safety profile remained favorable through Week 52, with no new or unexpected signals reported.
  • Biomea plans a new Phase 2 study in patients diagnosed within past 3 years, targeting initiation in second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604271737PRIMZONEFULLFEED9707986) on April 27, 2026, and is solely responsible for the information contained therein.